Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
RAS Mutation: early-phase trial registry
5 of 5 indexed RAS Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count
RAS Mutation: 5 US clinical trials tracked, 5 recruiting.
RAS Mutation is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is RasCal Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition ras-mutation
OPEN 5 | RECR 100% | LATE 0 | EARLY 4 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
RAS Mutation lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for RAS Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
RAS Mutation is recruiting above its size-band peers.
5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates RAS Mutation research.
RasCal Therapeutics accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical RAS Mutation enrolment sits around 134 participants.
Median target enrolment is 134 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
RAS Mutation research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
RASopathy Biorepository
Children's Hospital Medical Center, Cincinnati
NCT04395495
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics
NCT06922591
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics
NCT04678648
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Adlai Nortye Biopharma Co.
NCT07252479
PAS-004 in Patients With Advanced Solid Tumors
Pasithea Therapeutics
NCT06299839
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on RAS Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on RAS Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this RAS Mutation page
5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 RAS Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- RasCal Therapeutics sponsors the most RAS Mutation trials on record, review their full trial history before evaluating a specific study. See RasCal Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This RAS Mutation condition card totals 5 registered trials; most-linked intervention RSC-1255 Dose Expansion; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.